GHIT Fund's Strategic Investment in Portable Ebola Diagnostic Technology for Africa

GHIT Fund Invests in Rapid Diagnostic System for Ebola

In a significant move aimed at combating infectious diseases, the Global Health Innovative Technology (GHIT) Fund has announced a substantial investment of approximately JPY 140 million (around USD 862,000) in a joint project to develop a portable rapid diagnostic system for the Ebola disease. This initiative is a collaboration between Osaka Metropolitan University, K.K. DNAFORM, and the National Institute for Biomedical Research (INRB) of the Democratic Republic of the Congo.

Addressing the Ebola Threat

The urgency of this project is underscored by the ongoing outbreak caused by the Bundibugyo virus, prompting the World Health Organization (WHO) to declare a Public Health Emergency of International Concern (PHEIC) on May 16, 2026. In areas affected by the virus in the Democratic Republic of the Congo and Uganda, rapid testing of suspected Ebola cases has become crucial for timely isolation, contact tracing, and effective medical intervention. The need for point-of-care (POC) diagnostic tests, especially in regions lacking advanced laboratory infrastructure, cannot be overstated.

Details of the Investment

The GHIT Fund's investment will support early development milestones, including the creation of a prototype and validation of its effectiveness in detecting the Bundibugyo virus. This project aligns with the GHIT Fund's commitment to enhance rapid diagnostic technologies, particularly as part of the global response to health threats, including pandemics. With a clear focus on the deployment of medical countermeasures within a window of just 100 days upon identifying a new pathogen, this initiative marks a significant step toward addressing the challenges posed by infectious diseases.

Following a rapid assessment phase, the GHIT Fund opened a call for Expressions of Interest (EOIs), seeking innovative solutions in the realm of Rapid Diagnostic Tests (RDTs) and POC diagnostic development related to filovirus infections, which include Ebola. The application process has seen a flurry of promising submissions aimed at hastening product development, showcasing a collaborative effort to enhance health security.

Leveraging Innovative Technology

At the core of this project is the GenPad platform, an advanced isothermal nucleic acid amplification system developed by DNAFORM. This technology allows for the efficient detection of pathogens without the need for large equipment, making it suitable for use in outbreak settings where resources may be limited. By utilizing this portable platform, the project aims to create and assess a practical and effective POC testing system for Ebola.

The collaboration incorporates Osaka Metropolitan University’s extensive research network, DNAFORM’s technological expertise, and INRB’s established response framework to emerging infectious diseases, creating a holistic approach to tackle the current Bundibugyo virus outbreak. The synergy of these entities is expected to not only address the immediate crisis but also bolster preparedness for future Ebola outbreaks.

The Broader Impact of GHIT Fund

The GHIT Fund represents a proactive approach to global health challenges, formed as a public-private partnership (PPP) involving the Government of Japan, leading pharmaceutical companies, the Gates Foundation, Wellcome Trust, and the United Nations Development Programme (UNDP). Its mission is to invest in research and development portfolios that address neglected diseases impacting vulnerable populations around the world.

As initiatives like these unfold, the commitment towards developing diagnostics, vaccines, and therapeutics demonstrates the indispensable role of international collaboration in tackling infectious diseases. The collaboration on Ebola diagnostics not only highlights the importance of rapid response in healthcare but also reinforces the global community's obligation to safeguard public health against future threats.

For further information about this project, including its developments, you can consult the press releases from Osaka Metropolitan University and DNAFORM through their respective official websites.